These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19534284)

  • 1. Significantly increased accuracy of urothelial carcinoma detection in destained urine slides with combined analysis of standard cytology and CK-20 immunostaing.
    Soyuer I; Tokat F; Tasdemir A
    Acta Cytol; 2009; 53(3):357-60. PubMed ID: 19534284
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?
    Buchumensky V; Klein A; Zemer R; Kessler OJ; Zimlichman S; Nissenkorn I
    J Urol; 1998 Dec; 160(6 Pt 1):1971-4. PubMed ID: 9817302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Advances in Urine Cytology.
    Xing J; Reynolds JP
    Surg Pathol Clin; 2018 Sep; 11(3):601-610. PubMed ID: 30190143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
    McKenney JK; Desai S; Cohen C; Amin MB
    Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic value of cytohistological urine analysis and cytokeratin 20 in malignant and atypical urothelial cells.
    Negri S; Biavati P; Bondi A
    Pathologica; 2016 Sep; 108(3):130-135. PubMed ID: 28195264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
    Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
    Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
    Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
    Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomorphology of urothelial carcinomatous peritoneal effusion.
    Xiao GQ
    Cytopathology; 2008 Apr; 19(2):131-3. PubMed ID: 18241206
    [No Abstract]   [Full Text] [Related]  

  • 9. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
    Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
    Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD138-positive plasmacytoid urothelial carcinoma of the bladder.
    Patriarca C; Di Pasquale M; Giunta P; Bergamaschi F
    Int J Surg Pathol; 2008 Apr; 16(2):215-7. PubMed ID: 18417684
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review.
    Sanguedolce F; Russo D; Calò B; Cindolo L; Carrieri G; Cormio L
    Pathol Res Pract; 2019 Jun; 215(6):152413. PubMed ID: 30987832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.
    Babu S; Mockler DC; Roa-Peña L; Szygalowicz A; Kim NW; Jahanfard S; Gholami SS; Moffitt R; Fitzgerald JP; Escobar-Hoyos LF; Shroyer KR
    Mod Pathol; 2019 May; 32(5):717-724. PubMed ID: 30443013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of urinary bladder cancer with flow cytometry and hexaminolevulinate in urine samples.
    Cunderlíková B; Wahlqvist R; Berner A; Vasovic V; Warloe T; Nesland JM; Peng Q
    Cytopathology; 2007 Apr; 18(2):87-95. PubMed ID: 17397493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Antibody Comparison in Urothelial Carcinoma.
    Rijnders M; van der Veldt AAM; Zuiverloon TCM; Grünberg K; Thunnissen E; de Wit R; van Leenders GJLH
    Eur Urol; 2019 Mar; 75(3):538-540. PubMed ID: 30497882
    [No Abstract]   [Full Text] [Related]  

  • 16. Sensitivity and specificity of urine cytology in the screening of transitional cell carcinomas.
    Keir JA; Womack C
    Cytopathology; 2002 Dec; 13(6):381-2. PubMed ID: 12485176
    [No Abstract]   [Full Text] [Related]  

  • 17. The applicability and utility of immunohistochemical biomarkers in bladder pathology.
    Akgul M; MacLennan GT; Cheng L
    Hum Pathol; 2020 Apr; 98():32-55. PubMed ID: 32035992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nested variant of urothelial carcinoma.
    Dhall D; Al-Ahmadie H; Olgac S
    Arch Pathol Lab Med; 2007 Nov; 131(11):1725-7. PubMed ID: 17979494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of double immunocytochemical staining for CK20 and P53 as a potential adjunct to cytology for urothelial cancer diagnosis.
    Lenos M; Katafigiotis I; Vrettou K; Papaioannou D; Malta F; Trigka EA; Sousouris S; Constantinides C; Mikou P
    Cytopathology; 2017 Apr; 28(2):96-102. PubMed ID: 27859848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.